M
Maria I. Aguilar
Researcher at Mayo Clinic
Publications - 53
Citations - 6756
Maria I. Aguilar is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Stroke & Atrial fibrillation. The author has an hindex of 25, co-authored 51 publications receiving 6182 citations. Previous affiliations of Maria I. Aguilar include University of Texas Health Science Center at San Antonio.
Papers
More filters
Journal ArticleDOI
Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation
TL;DR: An updated meta-analysis of all currently available randomized trials that extends observations about the efficacy and safety of antithrombotic therapies for preventing stroke in patients who have atrial fibrillation is presented.
Journal ArticleDOI
Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion.
Maria I. Aguilar,Robert G. Hart,Carlos S. Kase,William D. Freeman,Barbara J. Hoeben,Rosa C. García,Jack Ansell,Stephan A. Mayer,Bo Norrving,Jonathan Rosand,Thorsten Steiner,Eelco F. M. Wijdicks,Takenori Yamaguchi,Masahiro Yasaka +13 more
TL;DR: All experts agreed that anticoagulation should be urgently reversed, but how to achieve it varied from use of prothrombin complex concentrates only to recombinant factor VIIa only, and all experts favored resumption of warfarin therapy within 3 to 10 days of ICH in stable patients in whom subsequent antICOagulation is mandatory.
Journal ArticleDOI
Oral anticoagulants for preventing stroke in patients with non‐valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks
Maria I. Aguilar,Robert G. Hart +1 more
TL;DR: Treatment with adjusted-dose warfarin to achieved INRs of 2 to 3 reduces stroke, disabling or fatal stroke, and death for patients with non-valvular AF and the benefits were not substantially offset by increased bleeding among participants in randomized clinical trials.
Journal ArticleDOI
Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks.
TL;DR: Adjusted-dose warfarin and related oral anticoagulants reduce stroke, disabling stroke and other major vascular events for those with non-valvular AF by about one third when compared with antiplatelet therapy.